Key result
Tyrosine kinase inhibitors linked to cardiovascular adverse events, requiring regular monitoring and cardio-oncology collaboration.
Why the study?
What are the cardiovascular complications associated with tyrosine kinase inhibitors and how can they be managed in clinical practice?
What are the cardiovascular complications associated with tyrosine kinase inhibitors and how can they be managed in clinical practice?
Answers are grounded in this paper and cite their sources.
Awareness, regular monitoring, and collaboration with cardiologists are essential to manage cardiovascular complications of tyrosine kinase inhibitors and maximize long-term therapeutic benefits.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Styczkiewicz et al. (2017) conducted a review in Hematological malignancies and solid tumors. Tyrosine kinase inhibitors was evaluated. Tyrosine kinase inhibitors are associated with cardiovascular adverse events such as hypertension, heart failure, and QT prolongation, requiring regular monitoring and cardio-oncology collaboration.
Synapse has enriched 10 related papers. Consider them for comparative context: